<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7917929</article-id><article-id pub-id-type="pmc">2033384</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fentiman</surname><given-names>I. S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Howell</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hamed</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>S. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ranson</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wall</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chaudary</surname><given-names>M. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ash</surname><given-names>C. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gregory</surname><given-names>W. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sellwood</surname><given-names>R. A.</given-names></name></contrib><etal/></contrib-group><aff>ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.</aff><pub-date pub-type="ppub"><month>10</month><year>1994</year></pub-date><volume>70</volume><issue>4</issue><fpage>729</fpage><lpage>731</lpage><abstract><p>A randomised clinical trial has been conducted to compare adjuvant tamoxifen, 20 mg daily, with tamoxifen and prednisolone, 7.5 mg daily, in post-menopausal women with operable breast cancer. There were 254 evaluable patients, of whom 128 were given tamoxifen alone and 126 received tamoxifen and prednisolone. After a median follow-up of 48 months there was no significant difference in relapse-free or overall survival of the two groups. Furthermore, with survival slightly favouring tamoxifen, confidence intervals on the hazard ratio established that a difference in favour of tamoxifen plus prednisolone of even 5% at 5 years was very unlikely (P &#x0003c; 0.02). Thus, despite the relatively small number of patients in this trial, the data clearly establish that prednisolone is not of value as an additional adjuvant agent.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00056-0159.tif" xlink:title="scanned-page" xlink:role="729" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00056-0160.tif" xlink:title="scanned-page" xlink:role="730" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00056-0161.tif" xlink:title="scanned-page" xlink:role="731" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

